Psychedelic

5-MeO-DMT

Extremely potent psychedelic tryptamine. Produces ego-dissolving experiences often described as more intense than N,N-DMT.

Important information

This information is for educational purposes only. Always research thoroughly, test your substances, understand legal implications, and consult healthcare professionals. Never use substances alone or in unsafe environments.

Dosage information

5-MeO-DMT · Vaporized · non-clinical reference ranges

Tier labels reproduce reported amount and intensity terminology; they do not indicate safety or a recommendation.

Reference dose ranges for 5-MeO-DMT by Vaporized, in milligrams
TierAmountNote
Threshold 2 to 5 milligrams
Light 5 to 10 milligrams
Common 10 to 15 milligrams
Strong 15 to 20 milligrams
Heavy Reported lower bound: 20 milligrams; no upper bound is established.

Dosage ranges are reference values from published literature, not recommendations. Potency varies by source, body weight, and individual sensitivity — harm-reduction practice starts well below the ranges listed.

Limitations: Figures are transcribed from a reference compilation, not measured in a controlled study; the potency of any given material is unknown until tested.

Evidence: Review or reference work

  1. Erowid Erowid 5-MeO-DMT Vault

Duration

15-45 minutes total | Peak: 5-20 minutes

Effect timeline · Vaporized
Onset 0m–1m Comeup 1m–3m Peak 5m–20m Offset 10m–30m Afterglow 15m–60m

15-45 minutes total. Peak: 5-20 minutes. Extremely intense.

Known interactions

Unsafe 5-MeO-DMT + MDMA (Ecstasy/Molly)

5-MeO-DMT is a potent serotonin agonist. Combined with MDMA's serotonin release, serotonin syndrome risk is significant.

Risks: Serotonin syndrome · Hyperthermia · Seizures · Extreme psychological distress

Mechanism: 5-MeO-DMT strongly agonizes 5-HT1A/2A. MDMA releases serotonin. Combined serotonergic load may cause toxicity.

What reduces the risk

  • Do not combine 5-MeO-DMT with MDMA
  • Allow at least 24 hours between use
  • 5-MeO-DMT should generally not be combined with other substances

Sources: PsychonautWiki: 5-MeO-DMT Interactions · TripSit Interaction Chart · Shulgin A, Shulgin A. TiHKAL. 1997

Unsafe 5-MeO-DMT + Kanna (Sceletium tortuosum)

Kanna's SRI properties combined with 5-MeO-DMT's strong serotonin agonism creates serotonin syndrome risk.

Risks: Serotonin syndrome · Hyperthermia · Seizures

Mechanism: Kanna inhibits serotonin reuptake while 5-MeO-DMT directly activates serotonin receptors, increasing synaptic serotonin to dangerous levels.

What reduces the risk

  • Do not combine
  • Allow at least 24 hours washout period

Sources: PsychonautWiki: 5-MeO-DMT Interactions · TripSit Interaction Chart

Absence of a listed interaction never implies safety. Check any combination in the app's 23×23 interaction matrix.

Harm reduction

  • Experienced sitter essential
  • Precise dosing critical
  • Safe physical environment
  • Test substance
  • Never combine with MAOIs or other substances
  • Mental health screening

Risks & side effects

  • Extreme intensity
  • Physical incapacitation
  • Respiratory depression risk
  • Psychological overwhelm
  • Dangerous combinations

Effects

  • Complete ego dissolution
  • Non-dual awareness
  • White light experiences
  • Timelessness
  • Unity consciousness

Schedule I in USA and most countries. Illegal to possess.

Pharmacology

Potent 5-HT1A and 5-HT2A agonist. Found in certain toads and plants.

Therapeutic research

  • Johns Hopkins: Survey study showing 80% of respondents reported improvements in anxiety and depression (Davis et al., 2019)
  • University of Maastricht: Naturalistic study showing sustained improvements in satisfaction with life and mindfulness (Uthaug et al., 2019)
  • Research into ego dissolution and mystical-type experiences as therapeutic mechanisms
  • Preliminary investigations into 5-MeO-DMT for substance use disorders
  • GH Research: Phase 1/2 clinical trial of synthetic 5-MeO-DMT (Mebufotenin) for treatment-resistant depression

Clinical studies 11

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

Jefferson et al. 2023 Neuropsychopharmacology study showing 5-MeO-DMT affects behavioral patterns and promotes dendritic spine growth in rodent brain tissue.

Fear as medicine: A mixed-methods analysis of 5-MeO-DMT, mental health, and intergenerational healing

Overall 2025 Applied Psychology Research. Mixed-methods analysis examining 5-MeO-DMT's role in mental health and intergenerational healing processes.

A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

Hayes 2025 Psychedelic Medicine. Review examining evidence for 5-MeO-DMT in depression treatment and its therapeutic potential.

Psychedelic treatment for alcohol misuse and PTSD in Special Operations Forces Veterans

Armstrong et al. 2023 Military Psychology study on psychedelic-assisted treatment for co-occurring alcohol misuse and PTSD in US Special Operations Forces Veterans.

Single inhalation of 5-MeO-DMT: Sustained enhancement of satisfaction with life and decrement of psychopathological symptoms

Uthaug et al. 2019 Psychopharmacology naturalistic study. Single vapor inhalation of toad-derived 5-MeO-DMT related to lasting improvements in life satisfaction and mindfulness.

Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment

Kargbo 2024 ACS Medicinal Chemistry Letters. Review of 5-MeO-DMT and DMT therapeutic potential, covering pharmacology, clinical development, and mental health applications.

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Barsuglia, Davis et al. 2018 Frontiers in Psychology. Showed 5-MeO-DMT produces mystical experiences comparable in intensity to high-dose psilocybin, with potential therapeutic implications.

Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

Lancelotta, Davis 2020 J Psychoactive Drugs. Survey examining how preparation and integration practices affect 5-MeO-DMT outcomes and long-term benefits.

5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous

Lancelotta 2022 Human Psychopharmacology. Critical safety warning about lethal risks of combining 5-MeO-DMT with MAOIs, clarifying 5-MeO-DMT is not present in traditional ayahuasca.

A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

Hayes 2025 Psychedelic Medicine. Commentary exploring the therapeutic potential of 5-MeO-DMT for depression treatment.

Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment

Kargbo 2024 ACS Medicinal Chemistry Letters. Review of therapeutic applications of 5-MeO-DMT and DMT for mental health treatment.

Sources 1

  1. Erowid Erowid 5-MeO-DMT Vault

History & culture

5-MeO-DMT has been used for centuries by indigenous peoples of the Orinoco Basin in South America as part of yopo and vilca snuffs prepared from Anadenanthera seeds. The Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) secretes 5-MeO-DMT in its venom glands — toad venom smoking rituals emerged in the 1980s, though claims of ancient indigenous toad use are disputed. The compound was first synthesized in 1936 by Toshio Hoshino. Its pharmacology was characterized in the 1950s–60s. The modern 5-MeO-DMT movement has raised conservation concerns about Sonoran Desert toad populations.

Natural origins

Found naturally in the venom of the Sonoran Desert toad (Incilius alvarius), native to northern Mexico and the southwestern United States. Also present in several plant species including Anadenanthera peregrina and Virola species. The toad secretes 5-MeO-DMT alongside bufotenin from parotoid glands as a defense mechanism. Conservation note: wild toad populations face pressure from collection — synthetic 5-MeO-DMT is chemically identical and avoids ecological harm. The compound also occurs endogenously in mammalian brains.

Molecular family: Tryptamines

Tryptamines are a class of indole-based compounds derived from tryptophan, an amino acid. This family includes some of the most powerful and well-studied psychedelics. The indole nucleus is conserved across all members, with variations in alkyl side chains and ring substitutions determining pharmacological effects. Tryptamines are found naturally in plants and fungi, with psilocybin being the most famous. Key characteristics: - Based on indole (benzene fused with pyrrole) - Often possess dimethylamino side chains - Range from mild (5-MeO-DMT) to extremely potent (DMT) - Found in nature: psilocybin mushrooms, ayahuasca, certain toads - Tend toward serotonergic mechanisms Members demonstrate remarkable diversity in intensity and duration despite similar core structure. Their indole foundation provides stability while allowing nature to create compounds spanning from gentle to overwhelming in effect.

Structurally related to Serotonin (5-HT)

External resources